GT BIOPHARMA, INC. Net Income (Loss) Available to Common Stockholders, Basic
GT BIOPHARMA, INC. (GTBP) reported Net Income (Loss) Available to Common Stockholders, Basic of -$4.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-14
- GT BIOPHARMA, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$4.59M.
- GT BIOPHARMA, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$3.37M.
- GT BIOPHARMA, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$7.52M.
- GT BIOPHARMA, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $4.10M.
- GT BIOPHARMA, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$34.45M.
- GT BIOPHARMA, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$13.16M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$4.59M 10-Q · filed 2026-08-14 | -$7.96M 10-Q · filed 2026-08-14 | -$15.48M derived: sum of 3 quarters · filed 2026-08-14 | -$11.38M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | -$3.37M 10-Q · filed 2026-05-15 | -$10.88M derived: sum of 2 quarters · filed 2026-05-15 | -$6.79M derived: sum of 3 quarters · filed 2026-05-15 | -$37.04M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | -$7.52M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | -$3.42M derived: sum of 2 quarters · filed 2026-03-06 | -$33.67M derived: sum of 3 quarters · filed 2026-08-14 | -$34.45M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $4.10M 10-Q/A · filed 2026-03-06 | -$3.26M 10-Q · filed 2025-11-14 | -$26.16M derived: sum of 2 quarters · filed 2026-08-14 | -$26.93M 10-Q/A · filed 2026-03-06 | -$5.55M 10-Q · filed 2025-11-14 | -$30.71M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | -$30.25M 10-Q · filed 2026-08-14 | -$1.52M 10-Q · filed 2025-08-14 | -$31.03M 10-Q · filed 2026-08-14 | -$2.29M 10-Q · filed 2025-08-14 | -$34.80M derived: sum of 3 quarters · filed 2026-08-14 | -$38.22M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$776.00K 10-Q · filed 2026-05-15 | -$4.55M derived: sum of 2 quarters · filed 2026-05-15 | -$7.96M derived: sum of 3 quarters · filed 2026-05-15 | -$11.67M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | -$3.77M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | -$7.19M derived: sum of 2 quarters · filed 2026-03-06 | -$10.90M derived: sum of 3 quarters · filed 2026-03-06 | -$13.16M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | -$3.41M 10-Q/A · filed 2026-03-06 | -$7.12M derived: sum of 2 quarters · filed 2026-03-06 | -$9.39M 10-Q/A · filed 2026-03-06 | ||||
| 2024-06-30 | -$3.71M 10-Q/A · filed 2026-03-06 | -$5.98M 10-Q/A · filed 2026-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |